Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes
- PMID: 15465415
- DOI: 10.1016/j.jcv.2004.03.015
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes
Abstract
Background: Naturally-occurring polymorphisms at the human immunodeficiency virus type 1 (HIV-1) protease which have been associated to resistance to protease inhibitors (PIs) in clade B viruses are frequently found in non-B subtypes, with unknown clinical significance.
Objective: To assess the susceptibility of non-B viruses to different PIs.
Study design: Plasma samples from 58 drug-naive individuals infected with HIV-1 non-B subtypes (2A, 22C, 2D, 1F, 29G and 2J) defined by phylogenetic analyses of the protease gene were tested using a phenotypic assay (PhenoSense, ViroLogic, South San Francisco, CA, USA). Twenty of them were further analyzed with another assay (Antivirogram, Virco, Mechelen, Belgium). All 58 non-B viruses harbored amino acid substitutions associated with reduced PI susceptibility in clade B (positions 10, 20, 36, 63, 70, 77 and 82).
Results: Using PhenoSense-HIV assay, all but two individuals harbored viruses completely susceptible to all six PIs tested (indinavir (IDV), ritonavir (RTV), saquinavir (SQV), nelfinavir (NFV), amprenavir (APV), lopinavir (LPV)). The two viruses with reduced susceptibility belonged to clade G. The first virus, which had K20I, M36I and V82I, showed 2.9-fold decreased susceptibility to APV, while the second virus showed 3.9-fold decreased susceptibility to both NFV and RTV, with amino acid substitutions K20I, M36I, L63P and V82I. Of note, several other viruses displayed the same constellation of mutations but without showing any reduced susceptibility, suggesting that these polymorphisms per se do not affect PI susceptibility.
Conclusion: PI susceptibility in HIV-1 non-B viruses seems to be preserved despite the presence of polymorphic changes which have been associated to PI resistance in clade B viruses.
Similar articles
-
Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.J Clin Virol. 2006 Aug;36(4):264-71. doi: 10.1016/j.jcv.2006.05.001. Epub 2006 Jun 12. J Clin Virol. 2006. PMID: 16765636
-
Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.Antivir Ther. 2006;11(4):457-63. Antivir Ther. 2006. PMID: 16856619 Clinical Trial.
-
Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.J Clin Virol. 2006 May;36(1):43-9. doi: 10.1016/j.jcv.2006.01.012. Epub 2006 Mar 24. J Clin Virol. 2006. PMID: 16563858
-
Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.Trop Med Int Health. 2008 Feb;13(2):144-51. doi: 10.1111/j.1365-3156.2007.01984.x. Trop Med Int Health. 2008. PMID: 18304259 Review.
-
Protease inhibition in African subtypes of HIV-1.AIDS Rev. 2003 Jul-Sep;5(3):165-71. AIDS Rev. 2003. PMID: 14598565 Review.
Cited by
-
Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia.BMC Infect Dis. 2014 Mar 22;14:158. doi: 10.1186/1471-2334-14-158. BMC Infect Dis. 2014. PMID: 24655349 Free PMC article.
-
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.AIDS. 2009 Apr 27;23(7):845-52. doi: 10.1097/QAD.0b013e328327957a. AIDS. 2009. PMID: 19276794 Free PMC article.
-
Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.AIDS Res Hum Retroviruses. 2011 Jan;27(1):71-80. doi: 10.1089/aid.2010.0050. Epub 2010 Oct 21. AIDS Res Hum Retroviruses. 2011. PMID: 20964479 Free PMC article.
-
Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.J Virol. 2013 Jan;87(1):454-63. doi: 10.1128/JVI.01211-12. Epub 2012 Oct 24. J Virol. 2013. PMID: 23097440 Free PMC article.
-
Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.J Int AIDS Soc. 2009 Oct 25;12:25. doi: 10.1186/1758-2652-12-25. J Int AIDS Soc. 2009. PMID: 19852859 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous